# JUL 1 6 2001 PH

# HE UNITED STATES PATENT AND TRADEMARK OFFICE

Philip John Burke and Richard John Knox

Serial No .:

09/445,865

Art Unit:

1642

Filed:

February 11, 2000

Examiner:

Nichol, G.

For:

THERAPEUTIC SYSTEMS

Assistant Commissioner for Patents Washington, D.C. 20231

## AMENDMENT AND TRANSMITTAL OF SEQUENCE LISTING

Sir:

Pursuant to 37 C.F.R. § 1.821-1.825, applicants enclose a 3 & 1/2" diskette containing a computer-readable form of the Sequence Listing as well as a paper copy of the Sequence Listing.

### **Amendment**

### In the Specification

Please amend the specification as follows.

On page 53, line 3, please delete the paragraph at lines 2 and 3 and insert in place thereof:

-Figure 6 shows the nucleotide sequence of a cDNA encoding human NQO2 and its

deduced amino acid sequence (SEQ ID NO:2).

On page 74, please delete the paragraph at lines 2 through 7 and insert in place thereof:

This was cloned into F58 cut NcoI/HindIII to produce the vector H1. F58 is a derivative of pBluescript II SK(+) (Stratagene) produced in house and incorporates an extra

1.

2 0 2001 NTER 1600/2900

1-42 7-28=1